Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1OSH

A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR

Summary for 1OSH
Entry DOI10.2210/pdb1osh/pdb
DescriptorBile acid receptor, METHYL 3-{3-[(CYCLOHEXYLCARBONYL){[4'-(DIMETHYLAMINO)BIPHENYL-4-YL]METHYL}AMINO]PHENYL}ACRYLATE (3 entities in total)
Functional Keywordsnuclear receptor, ligand binding domain, transcription
Biological sourceHomo sapiens (human)
Cellular locationNucleus (Probable): Q96RI1
Total number of polymer chains1
Total formula weight27583.72
Authors
Primary citationDownes, M.,Verdecia, M.A.,Roecker, A.J.,Hughes, R.,Hogenesch, J.B.,Kast-Woelbern, H.R.,Bowman, M.E.,Ferrer, J.-L.,Anisfeld, A.M.,Edwards, P.A.,Rosenfeld, J.M.,Alvarez, J.G.,Noel, J.P.,Nicolaou, K.C.,Evans, R.M.
A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR
Mol.Cell, 11:1079-1092, 2003
Cited by
PubMed Abstract: The farnesoid X receptor (FXR) functions as a bile acid (BA) sensor coordinating cholesterol metabolism, lipid homeostasis, and absorption of dietary fats and vitamins. However, BAs are poor reagents for characterizing FXR functions due to multiple receptor independent properties. Accordingly, using combinatorial chemistry we evolved a small molecule agonist termed fexaramine with 100-fold increased affinity relative to natural compounds. Gene-profiling experiments conducted in hepatocytes with FXR-specific fexaramine versus the primary BA chenodeoxycholic acid (CDCA) produced remarkably distinct genomic targets. Highly diffracting cocrystals (1.78 A) of fexaramine bound to the ligand binding domain of FXR revealed the agonist sequestered in a 726 A(3) hydrophobic cavity and suggest a mechanistic basis for the initial step in the BA signaling pathway. The discovery of fexaramine will allow us to unravel the FXR genetic network from the BA network and selectively manipulate components of the cholesterol pathway that may be useful in treating cholesterol-related human diseases.
PubMed: 12718892
DOI: 10.1016/S1097-2765(03)00104-7
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

237423

数据于2025-06-11公开中

PDB statisticsPDBj update infoContact PDBjnumon